Pfizer's Move: Should You Reconsider BNTX Stock?

Pfizer's decision to offload its remaining shares in BioNTech (BNTX) has raised eyebrows. This move hints at a lack of faith in BioNTech's COVID-19 vaccine and its stock potential. BioNTech, once a profit powerhouse, is now facing significant losses. Its shares, though not cheap, reflect a company struggling to find solid ground. BioNTech's star product, the COVID-19 vaccine Comirnaty, saw peak sales of $37. 8 billion in 2022. However, sales have since plummeted, with a 19% year-over-year decline in Q3 2025. This drop has pushed BioNTech into the red, reporting a net loss of $719. 9 million in 2024 and $33. 55 million in Q3 2025. Despite a boost from Bristol-Myers Squibb (BMY) payments related to their collaboration on BNT327, an immuno-oncology treatment, BioNTech's future remains uncertain. Analysts predict continued losses for BioNTech, with expected losses per share of $4. 10 in 2025 and $4. 04 in 2026. The company's shares trade at a price-sales ratio of 6. 8 times, indicating a high valuation relative to its sales. BioNTech's pipeline drugs, BNT327 and BNT323, show potential but come with significant challenges. BNT327, in a Phase 2 trial for extensive-stage small cell lung cancer, showed modest improvements in progression-free survival (PFS) and concerning adverse events at higher doses. BNT323, while meeting its primary endpoint in a Phase III trial for breast cancer, faces stiff competition from Enhertu, a similar drug already on the market. Pfizer's decision to sell its stake in BioNTech is a red flag. The company is losing money, and its pipeline drugs face significant hurdles. While Bristol-Myers Squibb's investment is encouraging, the data on BNT327 is not particularly strong. BNT323's success is uncertain given the competition from Enhertu. BioNTech's valuation is not particularly low, making it a risky investment. For now, BioNTech looks like a sell. However, if the company's drug candidates show significant progress and the stock price drops considerably, it might be worth reconsidering in the future.